PENDARVIS DAVID 4
4 · RESMED INC · Filed Jun 7, 2023
Insider Transaction Report
Form 4
RESMED INCRMD
PENDARVIS DAVID
Sr. VP, General Counsel
Transactions
- Sale
ResMed Common Stock
2023-06-05$219.79/sh−1,500$329,685→ 89,729 total
Footnotes (2)
- [F1]The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2022.
- [F2]Includes 56.7807 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan.